Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 10/20 | 0.58 |
| ▸ | HDAC6 | Q9UBN7 | 9/20 | 0.58 |
| ▸ | HDAC8 | Q9BY41 | 5/20 | 0.58 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.58 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.58 |
| ▸ | CA1 | P00915 | 2/20 | 0.58 |
| ▸ | NCOR2 | Q9Y618 | 2/20 | 0.58 |
| ▸ | CA12 | O43570 | 1/20 | 0.58 |
| ▸ | IDO1 | P14902 | 1/20 | 0.58 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.58 |
| ▸ | CA9 | Q16790 | 1/20 | 0.58 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.58 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.58 |
| ▸ | CA2 | P00918 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8496406 | 0.87 | HDAC6 (0.60) | HDAC1HDAC6HDAC8HDAC2HDAC3 | |
| SCHEMBL3673435 | 0.81 | HDAC6 (0.75) | HDAC1HDAC6HDAC8HDAC2HDAC3 | |
| SCHEMBL29061897 | 0.78 | HDAC6 (0.34) | HDAC1HDAC6HDAC8HDAC2HDAC3 | |
| SCHEMBL6564590 | 0.78 | MPO (0.58) | CA1CA9CA2 | |
| SCHEMBL19403 | 0.78 | HDAC8 (0.58) | HDAC6HDAC8HDAC2CA1CA12 | |
| SCHEMBL4188342 | 0.76 | NPC1 (0.52) | HDAC6HDAC8HDAC2HDAC3ALOX15 | |
| SCHEMBL1098645 | 0.76 | SCN9A (0.50) | HDAC1HDAC6 | |
| SCHEMBL8961322 | 0.75 | ALDH1A1 (0.33) | HDAC1HDAC6HDAC8HDAC2HDAC3 | |
| SCHEMBL25060935 | 0.74 | HDAC1 (0.75) | HDAC1HDAC6HDAC8HDAC2HDAC3 | |
| Benzohydroxamate SCHEMBL133061 | 0.74 | HDAC8 (1.00) | HDAC1HDAC6HDAC8HDAC2HDAC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 142 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2836484-B1 | HISTONE DEACETYLASES (HDACS) INHIBITORS | ANNJI PHARM CO LTD (CN) | 2017-06-14 | — | — | EP | claimed |
| EP-2318006-B1 | NOVEL PYRROLE INHIBITORS OF S-NITROSOGLUTATHIONE REDUCTASE AS THERAPEUTIC AGENTS | NIVALIS THERAPEUTICS INC (US) | 2016-10-12 | — | — | EP | claimed |
| CN-104364237-B | Histone deacetylase (HDACS) inhibitors | 安基生技新药股份有限公司 | 2016-08-24 | — | — | CN | claimed |
| US-9387209-B2 | Histone deacetylases (HDACs) inhibitors | Annji Pharmaceutical Co., Ltd. (TW) | 2016-07-12 | — | — | US | claimed |
| US-9155739-B2 | Histone deacetylases (HDACs) inhibitors | Annji Pharmaceutical Co., Ltd. (TW) | 2015-10-13 | — | — | US | claimed |
| US-9138427-B2 | Pyrrole inhibitors of S-nitrosoglutathione reductase as therapeutic agents | NIVALIS THERAPEUTICS, INC. (US) | 2015-09-22 | — | — | US | claimed |
| US-9115090-B2 | Zn2+-chelating motif-tethered short-chain fatty acids as a novel class of histone deacetylase inhibitors | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2015-08-25 | — | — | US | claimed |
| US-20150196563-A1 | HISTONE DEACETYLASES (HDACS) INHIBITORS | ANNJI PHARM CO LTD (TW) | 2015-07-16 | — | — | US | claimed |
| CN-104364237-A | Histone deacetylase (HDACS) inhibitors | ANNJI PHARM CO LTD | 2015-02-18 | — | — | CN | claimed |
| CN-101801949-B | Sulfonamides as TRPM8 modulators | JANSSEN PHARMACEUTICA NV | 2014-09-24 | — | — | CN | claimed |
| CN-101801949-A | Sulfonamides as TRPM8 modulators | JANSSEN PHARMACEUTICA NV | 2010-08-11 | — | — | CN | claimed |
| EP-2183239-A1 | SULFONAMIDES AS TRPM8 MODULATORS | Janssen Pharmaceutica, N.V. (BE) | 2010-05-12 | — | — | EP | claimed |
| WO-2010019903-A1 | NOVEL PYRROLE INHIBITORS OF S-NITROSOGLUTATHIONE REDUCTASE AS THERAPEUTIC AGENTS | N30 PHARMACEUTICALS, LLC (US) | 2010-02-18 | — | — | WO | claimed |
| US-20090264474-A1 | SULFONAMIDES AS TRPM8 MODULATORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2009-10-22 | — | — | US | claimed |
| WO-2009012430-A1 | SULFONAMIDES AS TRPM8 MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-01-22 | — | — | WO | claimed |
| EP-1996606-A1 | TROPOLONE- AND HYDROXYBENZENE-SUBSTITUTED OLIGOPEPTIDES FOR DEPIGMENTATION | Beiersdorf Aktiengesellschaft (DE) | 2008-12-03 | — | — | EP | claimed |
| US-20070225373-A1 | Zn2Motif-Tethered Short-Chain Fatty Acids as a Novel Class of Histone Deacetylase | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2007-09-27 | — | — | US | claimed |
| WO-2007101882-A1 | TROPOLONE- AND HYDROXYBENZENE-SUBSTITUTED OLIGOPEPTIDES FOR DEPIGMENTATION | BEIERSDORF AG (DE) | 2007-09-13 | — | — | WO | claimed |
| EP-1696898-A2 | ZN 24 -CHELATING MOTIF-TETHERED SHORT-CHAIN FATTY ACIDS AS A NOVEL CLASS OF HISTONE DEACETYLASE INHIBITORS | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2006-09-06 | — | — | EP | claimed |
| WO-2005055928-A2 | ZN2+ -CHELATING MOTIF-TETHERED SHORT -CHAIN FATTY ACIDS AS A NOVEL CLASS OF HISTONE DEACETYLASE INHIBITORS | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2005-06-23 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150196563-A1 | HISTONE DEACETYLASES (HDACS) INHIBITORS | HDAC1, HDAC3, HDAC11 | HDAC1 1/4885HDAC6 13/4885HDAC8 7/4885 |
| US-20070225373-A1 | Zn2Motif-Tethered Short-Chain Fatty Acids as a Novel Class of Histone Deacetylase | HDAC1, BAZ2B, HDAC11 | HDAC1 1/4885HDAC6 13/4885HDAC8 14/4885 |
| US-20090264474-A1 | SULFONAMIDES AS TRPM8 MODULATORS | TRPM8, TRPM5, TRPM2 | HDAC1 1045/4885HDAC6 802/4885HDAC8 218/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.